Want to join the conversation?
In 3Q15, excluding the impact of foreign currency, $BXLT's hematology & immunology businesses generated double-digit sales growth. Hematology revenues increased 10% to $935MM as it continues to focus on enhancing access and elevating standards of care worldwide; and Immunology sales advanced 12% to $626MM on a pro forma basis.
Any idea why some investors are happy about the disastrous $UA results??
Wow! GM killed it with earnings today! Did not expect this after $F gave the feeling it will eclipse the Chevy maker completely!
Oil rebound starting to show up in energy stocks. $XOM $CVX
I have a feeling "CLOUDy" days are ahead, with $AMZN leading the pack.
$AAL is giving pay hikes to its employees but investors are sulking.